TY - JOUR
T1 - Using qualitative, community-based input to steer post–coronavirus disease 2019 pharmacy practice in substance use
AU - Kosobuski, Lucas
AU - Hawn, Andrew
AU - France, Katelyn
AU - Chen, Nathaniel
AU - LaPlante, Cierra
AU - Palombi, Laura
N1 - Funding Information:
The authors acknowledge the contributions of student pharmacists Reid Larson and Sarah Christiansen and AmeriCorps VISTA Anna Van Deelen for their work in conducting interviews and Kaitlyn Erola for her work in transcribing interviews and data analysis.
Publisher Copyright:
© 2022 American Pharmacists Association®
PY - 2022
Y1 - 2022
N2 - Background: The coronavirus disease 2019 (COVID-19) pandemic has had a disproportionately negative impact on individuals with a substance use disorder (SUD). A rapidly changing public health and treatment environment has resulted in increased needs for pharmacist engagement in SUD-focused patient care. Objectives: This study used semistructured interviews of SUD professionals to evaluate where they believe pharmacy practice could better support people at risk of or having SUD in light of challenges posed by the COVID-19 pandemic. Methods: Professionals dedicated to the care of individuals with SUD were recruited from a large community substance use coalition to participate in a qualitative study examining how pharmacists could take a more active role in SUD prevention, intervention, recovery, and harm reduction (HR). A consensual qualitative research approach was used in data analysis. Results: Domains identified in analysis included pharmacists as educators of patients and communities, pharmacists as educators of health care providers, pharmacists as advocates for individuals with SUD, the need for increased pharmacist engagement owing to COVID-19 challenges for individuals with SUD, the need for expanded pharmacy practice interventions, and the need for pharmacist self-development. Conclusion: Increased medication counseling, HR practices, addressing stigma, and community-level education focused on SUD were among the most commonly reported areas for pharmacy practice development. In addition, the urgent need to adjust pharmacy practice in response to the COVID-19 pandemic was also identified by interviewees.
AB - Background: The coronavirus disease 2019 (COVID-19) pandemic has had a disproportionately negative impact on individuals with a substance use disorder (SUD). A rapidly changing public health and treatment environment has resulted in increased needs for pharmacist engagement in SUD-focused patient care. Objectives: This study used semistructured interviews of SUD professionals to evaluate where they believe pharmacy practice could better support people at risk of or having SUD in light of challenges posed by the COVID-19 pandemic. Methods: Professionals dedicated to the care of individuals with SUD were recruited from a large community substance use coalition to participate in a qualitative study examining how pharmacists could take a more active role in SUD prevention, intervention, recovery, and harm reduction (HR). A consensual qualitative research approach was used in data analysis. Results: Domains identified in analysis included pharmacists as educators of patients and communities, pharmacists as educators of health care providers, pharmacists as advocates for individuals with SUD, the need for increased pharmacist engagement owing to COVID-19 challenges for individuals with SUD, the need for expanded pharmacy practice interventions, and the need for pharmacist self-development. Conclusion: Increased medication counseling, HR practices, addressing stigma, and community-level education focused on SUD were among the most commonly reported areas for pharmacy practice development. In addition, the urgent need to adjust pharmacy practice in response to the COVID-19 pandemic was also identified by interviewees.
UR - http://www.scopus.com/inward/record.url?scp=85128157918&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85128157918&partnerID=8YFLogxK
U2 - 10.1016/j.japh.2022.03.014
DO - 10.1016/j.japh.2022.03.014
M3 - Article
C2 - 35428578
AN - SCOPUS:85128157918
JO - Journal of the American Pharmaceutical Association. American Pharmaceutical Association
JF - Journal of the American Pharmaceutical Association. American Pharmaceutical Association
SN - 1544-3191
ER -